Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies Inc (ALUR) delivers innovative weight management solutions through its swallowable gastric balloon and integrated digital platform. This page provides authorized updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of non-invasive obesity treatment.
Investors and healthcare professionals will find timely announcements including quarterly earnings reports, FDA regulatory updates, partnerships with medical institutions, and new clinical study findings. Our curated news collection ensures transparent access to material events affecting the company's position in the medical device sector.
Key content categories include product innovation timelines, peer-reviewed research publications, executive leadership changes, and global expansion updates. Each announcement is sourced directly from official corporate communications to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Allurion's latest developments in AI-powered patient monitoring systems and procedure-less weight loss technologies. Regularly updated to reflect the company's progress in merging medical devices with digital health solutions.
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE:ALUR) has appointed Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan brings 20 years of experience as a legal and compliance officer at public companies, with his most recent role at Acushnet Company. In this new role, Brendan will lead the company’s legal and compliance strategies, guiding its global expansion and commitment to delivering safe and effective weight loss solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. has announced that Somerset NHS Foundation Trust is the first NHS trust in the UK to introduce the Allurion Gastric Balloon, a swallowable gastric balloon that requires no surgery, endoscopy, or anesthesia. The balloon helps patients lose 10-15% of their body weight in 4 months and is proven to be safe and effective. The Allurion Program is particularly effective for patients with a higher BMI and is expected to save the NHS significant time and money compared to bariatric surgery. The program also includes an AI-powered behavior change program and 1-1 support from doctors and nutritionists. The partnership between Allurion and the NHS addresses the need for scalable, evidence-based weight solutions in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the introduction of the Allurion Gastric Balloon by the Somerset NHS Foundation Trust, marking the first time a non-private sector organization in the world has introduced this innovative swallowable gastric balloon. The balloon, which is filled and remains in the stomach for approximately 4 months, has been proven to help patients lose an average of 10-15% of their body weight. The treatment is expected to save the NHS significant time and money as it is substantially less expensive than bariatric surgery. The partnership between Allurion and the NHS aims to provide a weight loss solution that does not tap into surgical or endoscopic resources that are already overbooked and constrained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) has expanded its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups. The VCS has shown positive results in increasing patient accountability, practice efficiency, and patient engagement, with clinics reporting an average 11% additional weight loss and over 16% additional patients reaching their goals. This expansion underscores the growing opportunities for the digital platform since launching Coach Iris—Allurion’s 24/7 AI-powered weight loss coach. The VCS now provides 24/7 coaching and guidance to patients across multiple modalities of care, including anti-obesity medications, devices, and bariatric surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the publication of a study demonstrating significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. Weight loss was 13.7% at 4 months, with resolution of type 2 diabetes, hypertension, and obstructive sleep apnea observed in 55.5%, 58.8%, and 57.8%, respectively. Results improved with the addition of oral GLP-1 agonist semaglutide, with weight loss improving to 17.6% and co-morbidity resolution improving to 64.7%, 64.3%, and 72%, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
News
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announces substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program. The company also prioritizes key investments in strategic markets and digital innovations ahead of FDA milestones. Preliminary unaudited results for the fourth quarter and full year 2023 show a 30% procedure volume growth, reflecting significant demand for the Allurion Program. CEO Dr. Shantanu Gaur emphasizes the company's focus on reducing cost structure, optimizing capital structure, and accelerating the path to profitability in the 2024 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the results of research on the impact of the changing weight-loss market on the Allurion Program. The research included 172 healthcare professionals and 1663 patients across 64 countries. Almost 90% of HCPs believed the Allurion Program was an ideal first-line treatment to achieve >10% body weight loss in a fast and sustainable way. The global market for anti-obesity medications, specifically GLP-1s, is expected to reach $100 billion by 2030. The survey results highlighted a belief among HCPs that the introduction of anti-obesity medications like GLP-1s had a positive impact on raising awareness of, and generating interest in, other medical weight-loss treatment options, including the Allurion Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE:ALUR) announces expanded commercial agreement with Weight Doctors and hiring of Brian Conyer to lead commercialization of digital assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced its financial results for Q3 2023, reporting a 40% sequential revenue growth and completion of business combination with Compute Health. The company also launched Coach Iris, an AI-powered weight loss coach, and completed enrollment in the AUDACITY trial for Allurion Balloon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) will be participating in the Jefferies London Healthcare Conference on November 14-16, 2023. The company's CEO and CFO will present on November 15 at 9:30 a.m. GMT and will be available for investor meetings. A live webcast of the event will be available on the Allurion website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
ALLURION TECHNOLOGIES INC
NYSE:ALUR
ALUR Rankings
ALUR Stock Data
13.95M
5.09M
13.85%
22.25%
2.11%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
NATICK